Y-mAbs Therapeutics
YMAB
About: Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Employees: 107
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7,450% more call options, than puts
Call options by funds: $151K | Put options by funds: $2K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1% less capital invested
Capital invested by funds: $128M [Q1] → $126M (-$1.76M) [Q2]
2.1% less ownership
Funds ownership: 63.7% [Q1] → 61.6% (-2.1%) [Q2]
6% less funds holding
Funds holding: 102 [Q1] → 96 (-6) [Q2]
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
HC Wainwright & Co.
Robert Burns
|
$8.6
|
Neutral
Downgraded
|
6 Aug 2025 |
|
Canaccord Genuity
Bill Maughan
|
$8.6
|
Hold
Downgraded
|
6 Aug 2025 |
Financial journalist opinion
